[30 October 2012, Hong Kong] Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or the “Company” and, together with its subsidiaries, the “Group”), a leading healthcare company in the PRC, has been officially listed and commenced trading on the Main Board of the Stock Exchange of Hong Kong Limited (“HKEx”) today.

 

Shares of Fosun Pharma were actively traded. An aggregate turnover of approximately HK$589 million was traded. The H-shares offering of Fosun Pharma is one of the most successful IPO in the Hong Kong market this year, especially being the first IPO project with a scale of over USD500 million in the past 3 months. It is known as the ice-breaking issue of the Hong Kong IPO market, which further boosted confidence in the market and became an important milestone for the Company to enter the international capital market.

 

Fosun Pharma strengthened the corporate governance and investor relationship management, and therefore achieved significant outcome. Besides SSE 180 Index, CSI 300 Index, SSE Dividend Index, SSE Corporate Governance Index, Fosun Pharma has also been successfully included in the SSE Private Enterprise 50 Index and SSE Social Responsibility Index. According to IMS Health Incorporated (“IMS”), the Group was one of the top five domestic pharmaceutical companies in the PRC by revenue from the pharmaceutical manufacturing segment in 2011. The Group’s business operations strategically cover multiple important segments in the healthcare industry value chain, with business segments include pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services, and diagnostic products and medical devices. The Group has maintained a relatively high growth, which promised a huge potential to grow.

 

UBS AG, Hong Kong Branch (“UBS”), China International Capital Corporation Hong Kong Securities Limited (“CICC”), J.P. Morgan Securities (Asia Pacific) Limited (“JPM”) and Deutsche Bank AG, Hong Kong Branch (“DB”) are the Joint Global Coordinators, UBS Securities Hong Kong Limited, CICC, J.P. Morgan Securities (Far East) Limited and DB are the Joint Sponsors , UBS, CICC, JPM and DB are the Joint Bookrunners and Joint Lead Managers for the Hong Kong Public Offering, UBS, CICC, J.P. Morgan Securities plc, DB, ABCI Securities Company Limited and Haitong International Securities Company Limited are the Joint Bookrunners and Joint Lead Managers for the International Offering in the global offering.

 

Mr. Chen Qiyu, Executive Director and Chairman of Fosun Pharma, said, “Fosun Pharma has been the world's second largest IPO in the pharmaceutical industry since. Upon our listing, we are the third China’s healthcare company listed on the main boards of both HKEx and Shanghai Stock Exchange. We are honored to have the support from the investors during the global offering. Being a leading healthcare company in the PRC, we will endeavor to seize market opportunities, actively optimize existing business, continue to invest in innovative research and development and increase our market share in the pharmaceutical manufacturing and other business segments in the PRC market. Leveraging our Group’s competitive advantages and future development strategies, we are well positioned to seize opportunities in the China’s pharmaceutical market, which is among those with the highest growth potential in the world. We aim to become a first-tier enterprise in the global mainstream pharmaceutical market and reward our investors with the greatest benefits. We are confident in the rapid development of the Company's operating performance.”

 

Being the largest shareholder of Fosun Pharma, Fosun International Limited (“Fosun International”) has been very supportive to the H-share offering of the Company. Mr. Guo Guangchang, Chairman of Fosun International said, “Fosun International is very pleased that Fosun Pharma has been successfully listed in Hong Kong. We fully support Fosun Pharma to enter the Hong Kong capital market. The Group believes that the successful listing of Fosun Pharma can offer the investors a unique investment opportunity in China’s pharmaceutical and healthcare industries, and share the benefits of the rapid growth in China’s pharmaceutical field with both domestic and foreign investors.”